Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Price Target at $117.00

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $117.00.

Several analysts recently weighed in on COO shares. Wells Fargo & Company boosted their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Morgan Stanley reduced their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Citigroup lowered their price objective on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Finally, StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th.

Cooper Companies Price Performance

Shares of COO stock opened at $90.31 on Thursday. The business has a fifty day simple moving average of $97.84 and a 200 day simple moving average of $98.84. The company has a market cap of $18.02 billion, a P/E ratio of 46.31, a P/E/G ratio of 2.40 and a beta of 0.99. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The firm’s revenue was up 9.8% compared to the same quarter last year. On average, sell-side analysts forecast that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of COO. Commonwealth Equity Services LLC boosted its position in Cooper Companies by 0.8% during the second quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 118 shares during the period. Acadian Asset Management LLC increased its position in shares of Cooper Companies by 206.3% in the second quarter. Acadian Asset Management LLC now owns 2,205 shares of the medical device company’s stock worth $191,000 after purchasing an additional 1,485 shares during the last quarter. Varma Mutual Pension Insurance Co purchased a new stake in shares of Cooper Companies during the 2nd quarter valued at $1,746,000. Prudential PLC raised its position in Cooper Companies by 16.1% during the second quarter. Prudential PLC now owns 64,404 shares of the medical device company’s stock valued at $5,622,000 after purchasing an additional 8,921 shares in the last quarter. Finally, Wedbush Securities Inc. boosted its holdings in shares of Cooper Companies by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 13,296 shares of the medical device company’s stock worth $1,161,000 after purchasing an additional 1,240 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.